Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Curtis A. Lachowiez"'
Autor:
Danielle Hammond, Sanam Loghavi, Sa A. Wang, Marina Y. Konopleva, Tapan M. Kadia, Naval G. Daver, Maro Ohanian, Ghayas C. Issa, Yesid Alvarado, Nicholas J. Short, Koji Sasaki, Naveen Pemmaraju, Guillermo Montalban-Bravo, Curtis A. Lachowiez, Abhishek Maiti, Guillermo Garcia-Manero, Elias J. Jabbour, Gautam Borthakur, Farhad Ravandi, Koichi Takahashi, Sherry R. Pierce, Hagop M. Kantarjian, Courtney D. DiNardo
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-4 (2023)
Externí odkaz:
https://doaj.org/article/b7c6599d1ff945fc8f42960c8b15f42e
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (VEN) in combination with lower-intensity therapy is an efficacious treatment for acute myeloid leukemia (AML). VEN in combination with the hypomethylating agent azacitidine improved rates of respons
Externí odkaz:
https://doaj.org/article/847f902f528c4887bc3f101b7f74244c
Autor:
Curtis A. Lachowiez, Patrick K. Reville, Hagop Kantarjian, Elias Jabbour, Gautam Borthakur, Naval Daver, Ghayas Issa, Ken Furudate, Tomoyuki Tanaka, Sherry Pierce, Guilin Tang, Keyur P. Patel, Jeffrey Medeiros, Hussein A. Abbas, Fadi Haddad, Daniel Hammond, Nicholas J. Short, Abhishek Maiti, Musa Yilmaz, Koji Sasaki, Koichi Takahashi, Naveen Pemmaraju, Marina Konopleva, Guillermo Garcia‐Manero, Farhad Ravandi, Tapan M. Kadia, Sanam Loghavi, Courtney D. DiNardo
Publikováno v:
American Journal of Hematology. 97:1443-1452
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b7c504cda44d01abc4bb3261b240b6a
https://doi.org/10.1002/ajh.26694
https://doi.org/10.1002/ajh.26694
Autor:
Curtis A. Lachowiez, Sanam Loghavi, Zhihong Zeng, Tomoyuki Tanaka, Yi June Kim, Hidetaka Uryu, Sven Turkalj, Niels Asger Jakobsen, Marlise R. Luskin, Dzifa Y. Duose, Rebecca S S. Tidwell, Nicholas J. Short, Gautam Borthakur, Tapan M. Kadia, Lucia Masarova, George D. Tippett, Prithviraj Bose, Elias J. Jabbour, Farhad Ravandi, Naval G. Daver, Guillermo Garcia-Manero, Hagop Kantarjian, Jacqueline S. Garcia, Paresh Vyas, Koichi Takahashi, Marina Konopleva, Courtney D. DiNardo
Publikováno v:
Blood Cancer Discovery.
The safety and efficacy of combining the IDH1 inhibitor ivosidenib (IVO) with the BCL2 inhibitor venetoclax (VEN; IVO+VEN) +/- azacitidine (AZA; IVO+VEN+AZA) was evaluated in four cohorts of patients with IDH1-mutated myeloid malignancies (n=31). Mos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a2ef2e5e66589607245ebefd8e9103d
https://doi.org/10.1158/2643-3230.bcd-22-0205
https://doi.org/10.1158/2643-3230.bcd-22-0205
Autor:
Sai Prasad Desikan, Marina Konopleva, Koichi Takahashi, Curtis A Lachowiez, Sanam Loghavi, Lian-Chun Xiao, Tapan M. Kadia, Naval Daver, Nicholas Short, Koji Sasaki, Gautam Borthakur, Ghayas C. Issa, Abhishek Maiti, Kelly S. Chien, Yesid Alvarado, Guillermo Montalban-Bravo, Lucia Masarova, Musa Yilmaz, Michael Andreeff, Elias Jabbour, Guillermo Garcia-Manero, Steven M. Kornblau, Farhad Ravandi, Hagop Kantarjian, Courtney D. DiNardo
Publikováno v:
Blood. 140:534-536
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::446eb89d5e585c4e1658719ac126a483
https://doi.org/10.1182/blood-2022-164922
https://doi.org/10.1182/blood-2022-164922
Autor:
Sanam Loghavi, Patrick K Reville, Curtis A Lachowiez, Mark Routbort, Keyur Patel, Rashmi Kanagal-Shamanna, Chi Young Ok, Joseph D. Khoury, Guilin Tang, Sa A Wang, Tapan M. Kadia, Naval Daver, Koichi Takahashi, Guillermo Garcia-Manero, Sherry A. Pierce, Marina Konopleva, L. Jeffrey Medeiros, Hagop Kantarjian, Farhad Ravandi, Nicholas Short, Courtney D. DiNardo
Publikováno v:
Blood. 140:6306-6308
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57cd80287184498fcf9c8c6b37450f7e
https://doi.org/10.1182/blood-2022-164494
https://doi.org/10.1182/blood-2022-164494
Autor:
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, Elias Jabbour, Gautam Borthakur, Naval Daver, Sanam Loghavi, Ken Furudate, Lianchun Xiao, Sherry Pierce, Nicholas J Short, Abhishek Maiti, Musa Yilmaz, Koji Sasaki, Koichi Takahashi, Marina Konopleva, Naveen Pemmaraju, Uday Popat, Elizabeth Shpall, Guillermo Garcia-Manero, Farhad Ravandi, Courtney D DiNardo, Tapan M Kadia
Publikováno v:
The Lancet Haematology. 9:e350-e360
Venetoclax combined with intensive chemotherapy has been shown to be safe with promising activity in fit patients with newly diagnosed acute myeloid leukaemia. The aim of this study was to compare the activity of venetoclax plus intensive chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af632e6e462d6e006ce97e5edb70c2f9
https://doi.org/10.1016/s2352-3026(22)00076-x
https://doi.org/10.1016/s2352-3026(22)00076-x
Autor:
Curtis A. Lachowiez, Nicola Long, Jennifer Saultz, Arpita Gandhi, Laura F. Newell, Brandon Hayes-Lattin, Richard T. Maziarz, Jessica Leonard, Daniel Bottomly, Shannon McWeeney, Jennifer Dunlap, Richard Press, Gabrielle Meyers, Ronan Swords, Rachel J. Cook, Jeffrey W. Tyner, Brian J. Druker, Elie Traer
Publikováno v:
Blood advances.
Risk stratification in acute myeloid leukemia (AML) remains principle for survival prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) recommendations were recently published, with notable updates to risk group assignment. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bd5ab4b230718af1d7c207b9e6db2f2
https://pubmed.ncbi.nlm.nih.gov/36441905
https://pubmed.ncbi.nlm.nih.gov/36441905
Autor:
Curtis A, Lachowiez, Patrick K, Reville, Hagop, Kantarjian, Elias, Jabbour, Gautam, Borthakur, Naval, Daver, Ghayas, Issa, Ken, Furudate, Tomoyuki, Tanaka, Sherry, Pierce, Guilin, Tang, Keyur P, Patel, Jeffrey, Medeiros, Hussein A, Abbas, Fadi, Haddad, Daniel, Hammond, Nicholas J, Short, Abhishek, Maiti, Musa, Yilmaz, Koji, Sasaki, Koichi, Takahashi, Naveen, Pemmaraju, Marina, Konopleva, Guillermo, Garcia-Manero, Farhad, Ravandi, Tapan M, Kadia, Sanam, Loghavi, Courtney D, DiNardo
Publikováno v:
American journal of hematologyREFERENCES. 97(11)
Isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) mutations occur frequently in newly diagnosed (ND) acute myeloid leukemia (AML) often with co-occurring NPM1 mutations, which may influence treatment outcomes. Detailed analysis of IDH-mutated AML treate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b1385f8ff56e6909e2674487258179a9
https://pubmed.ncbi.nlm.nih.gov/36054614
https://pubmed.ncbi.nlm.nih.gov/36054614
Publikováno v:
Cancers. 15:1617
Treatment for acute myeloid leukemia (AML) has evolved rapidly over the last decade as improved understanding of cytogenetic and molecular drivers of leukemogenesis refined survival prognostication and enabled development of targeted therapeutics. Mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abc42673043cc8dd18dda734a7701b03
https://doi.org/10.3390/cancers15051617
https://doi.org/10.3390/cancers15051617